349 related articles for article (PubMed ID: 25369750)
1. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
2. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.
Krausz Y; Keidar Z; Kogan I; Even-Sapir E; Bar-Shalom R; Engel A; Rubinstein R; Sachs J; Bocher M; Agranovicz S; Chisin R; Israel O
Clin Endocrinol (Oxf); 2003 Nov; 59(5):565-73. PubMed ID: 14616879
[TBL] [Abstract][Full Text] [Related]
3. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
5. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors.
Perri M; Erba P; Volterrani D; Lazzeri E; Boni G; Grosso M; Mariani G
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):323-33. PubMed ID: 18480741
[TBL] [Abstract][Full Text] [Related]
6. Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT.
Ruf J; Steffen I; Mehl S; Rosner C; Denecke T; Pape UF; Plotkin M; Amthauer H
Nucl Med Commun; 2007 Oct; 28(10):782-8. PubMed ID: 17728608
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
8. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.
Wong KK; Cahill JM; Frey KA; Avram AM
Acad Radiol; 2010 Mar; 17(3):291-7. PubMed ID: 19962915
[TBL] [Abstract][Full Text] [Related]
9. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity?
Steffen IG; Mehl S; Heuck F; Elgeti F; Furth C; Amthauer H; Ruf J
Clin Nucl Med; 2009 Dec; 34(12):869-73. PubMed ID: 20139819
[TBL] [Abstract][Full Text] [Related]
10. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors.
Wong KK; Wynn EA; Myles J; Ackermann RJ; Frey KA; Avram AM
Clin Nucl Med; 2011 Jan; 36(1):25-31. PubMed ID: 21157203
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
12. Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors.
Kubota K; Okasaki M; Minamimoto R; Miyata Y; Morooka M; Nakajima K; Sato T
Ann Nucl Med; 2014 Dec; 28(10):1004-10. PubMed ID: 25179521
[TBL] [Abstract][Full Text] [Related]
13. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
[TBL] [Abstract][Full Text] [Related]
14. SPECT/CT stabilizes the interpretation of somatostatin receptor scintigraphy findings: a retrospective analysis of inter-rater agreement.
Apostolova I; Riethdorf S; Buchert R; Derlin T; Brenner W; Mester J; Klutmann S
Ann Nucl Med; 2010 Jul; 24(6):477-83. PubMed ID: 20449694
[TBL] [Abstract][Full Text] [Related]
15. The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours.
Jilesen AP; Hoefnagel SJ; Busch OR; Bennink RJ; Gouma DJ; Nieveen van Dijkum EJ
Clin Radiol; 2016 Jun; 71(6):537-42. PubMed ID: 27016111
[TBL] [Abstract][Full Text] [Related]
16. Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors.
Ueki Y; Otsuka H; Otani T; Kasai R; Otomi Y; Ikemitsu D; Azane S; Kunikane Y; Bando T; Matsuda N; Okada Y; Takayama T; Harada M
Jpn J Radiol; 2024 May; 42(5):519-535. PubMed ID: 38345724
[TBL] [Abstract][Full Text] [Related]
17. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
18. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
19. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
[TBL] [Abstract][Full Text] [Related]
20. Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy.
Moreira AP; Duarte LH; Vieira F; João F; Lima JP
Rev Esp Med Nucl; 2005; 24(1):14-8. PubMed ID: 15701341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
